×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RCUS – arcus biosciences, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RCUS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Low
Report
Arcus Biosciences Announces New Employment Inducement Grants
11/9
10:22 am
rcus
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report [Yahoo! Finance]
11/7
02:31 am
rcus
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
Neutral
Report
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
11/6
04:30 pm
rcus
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update [Yahoo! Finance]
Low
Report
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update [Yahoo! Finance]
11/6
04:22 pm
rcus
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Medium
Report
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
11/6
08:07 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Arcus Biosciences, Inc. (NYSE: RCUS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
11/5
09:00 am
rcus
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
Low
Report
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
11/5
07:56 am
rcus
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
09:51 am
rcus
Form SC 13G/A Arcus Biosciences, Inc. Filed by: FMR LLC
Medium
Report
Form SC 13G/A Arcus Biosciences, Inc. Filed by: FMR LLC
11/8
05:32 pm
rcus
Form SC 13G/A Arcus Biosciences, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A Arcus Biosciences, Inc. Filed by: BlackRock, Inc.
11/6
04:26 pm
rcus
Form 10-Q Arcus Biosciences, Inc. For: Sep 30
Low
Report
Form 10-Q Arcus Biosciences, Inc. For: Sep 30
11/6
04:24 pm
rcus
Form 8-K Arcus Biosciences, Inc. For: Nov 06
Medium
Report
Form 8-K Arcus Biosciences, Inc. For: Nov 06
10/24
04:11 pm
rcus
Form 8-K Arcus Biosciences, Inc. For: Oct 24
Medium
Report
Form 8-K Arcus Biosciences, Inc. For: Oct 24
10/23
05:05 pm
rcus
Form SC 13G/A Arcus Biosciences, Inc. Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G/A Arcus Biosciences, Inc. Filed by: BlackRock, Inc.
10/17
11:31 am
rcus
Form SC 13G/A Arcus Biosciences, Inc. Filed by: STATE STREET CORP
Low
Report
Form SC 13G/A Arcus Biosciences, Inc. Filed by: STATE STREET CORP
9/17
06:42 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Sep 15 Filed by: Nuyten Dimitry SA
Low
Report
Form 4 Arcus Biosciences, Inc. For: Sep 15 Filed by: Nuyten Dimitry SA
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/26
Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Mizuho. They set a "buy" rating on the stock.
15.6%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
TOP News Decliners
3/14
Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
-24.3%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: